ipilimumab,nivolumab,pembrolizumab
bms,merck
['niche2']
#esmo22 research seems great, real life - not so. during presidential session ii, prof. alex eggermont urged education in the larger medical community to consider neoadjuvant therapy before performing useless surgery in metastatic patients: swog s1801 and niche2! 
Ph.D biologist and #Melanoma Patient Advocate